

### WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit
Ministry of Health & Mass Media
231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 52 No. 20

10th - 16th May 2025

**Strengthening National Health Laboratory Services in Sri Lanka:** Aligning National Efforts with Global and Regional Standards



Figure 1. Framework of Laboratory Partners Source: CDC Partners with Laboratories for Readiness and

 $Response. \\ CDC\ Laboratories.\ https://www.cdc.gov/labs/partners/index.html$ 

Health laboratory services are vital for disease surveillance, outbreak detection, diagnosis, and monitoring. They form a foundation for broader health system strengthening. Globally and regionally, efficient laboratory systems are essential for achieving Universal Health Coverage (UHC) and meeting the International Health Regulations (IHR 2005). Strengthening health laboratory services in Sri Lanka requires a multisectoral approach involving hospitals, public health institutions, commercial and veterinary labs and academia. Aligning with the global framework (Figure 1), improved coordination, quality systems, workforce development, and expanded testing capacity, including point-ofcare and mobile testing, are key to enhancing readiness and response to public health emergencies.

In Sri Lanka, the health laboratory network is anchored by the Medical Research Institute (MRI). Further, it serves as the national reference laboratory. It offers diagnostic and research services in communicable disease surveillance, including Measles, Rubella, Influenza, Dengue, Typhoid, Japanese Encephalitis, and COVID-19 etc. Other services include food

and water microbiology, outbreak investigations, genomic surveillance, and nutritional assessments. MRI also leads to external quality assurance and laboratory capacity building.

Despite these strengths, Sri Lanka faces challenges such as fragmented services, limited integration, and resource constraints. These issues are especially evident outside vertical disease control programs. There is an urgent need to align national laboratory systems with global and regional frameworks. This article summarises the WHO and Asia Pacific strategies for laboratory system strengthening. It also reviews national priorities and identifies gaps. The goal is to highlight the importance of laboratories in health security and guide future investment, capacity building, and integration efforts.

#### Global Perspective: WHO's Framework for **Laboratory System Strengthening**

The World Health Organization (WHO) supports countries in strengthening laboratory systems across preparedness, response, and recovery. WHO guidance emphasizes developing national policies, regulatory frameworks, and governance structures. It promotes enhancing lab institutions and networks to support both daily healthcare needs and epidemic responses.

Workforce development is a core component. WHO helps countries build a trained, competent lab workforce for timely and accurate diagnostics. It also assists with biosafety, biosecurity, specimen transport, and Laboratory Quality Management Systems (LQMS). WHO facilitates simulation exercises, proficiency testing, and external quality assessments (EQA).

Despite advances in technology, biosafety and biosecurity remain weak in many countries. WHO provides guidance, training, and tools to address biological risk management. . It supports safe transport of infectious substances and helps laboratories meet accreditation standards (WHO, 2011; WHO, 2020).



- 1. Strengthening National Health Laboratory Services in Sri Lanka: Aligning National Efforts with Global and Regional Standards
- 2. Summary of selected notifiable diseases reported (03rd May 09th May 2025)
- 3. Surveillance of vaccine preventable diseases & AFP (03rd May 09th May 2025)

3 4

# Regional Context: Asia Pacific Strategy for Strengthening Health Laboratory Services

In the Asia Pacific Region, laboratory systems often evolved around disease-specific programs such as polio, HIV/AIDS, TB, and malaria. While effective for targeted control, this approach led to fragmentation and underinvestment. National-level coordination was often limited.

The Asia Pacific Strategy (2010–2015) proposed an integrated, system-wide approach. It emphasized the need for national policies, strategic planning, and governance. A key recommendation was developing tiered laboratory networks with defined roles, infrastructure, and referral systems.

The strategy also prioritized equitable financing. It promoted pooled funding over user fees to ensure accessibility. Capacity building was emphasized, especially in biosafety, diagnostics, quality assurance, and research. WHO support was encouraged for planning and coordination (WHO WPRO, 2010).

## National Landscape: Sri Lanka's Approach to Laboratory System Strengthening

Sri Lanka is making structured efforts to improve laboratory services. These align with global and regional standards and cover policy, infrastructure, workforce, digital transformation, and data use.

#### **National Health Laboratory Policy (2006)**

This policy provides a framework for laboratory services across all levels. It sets national standards for infrastructure, diagnostics, and equipment. It also proposes a National External Quality Assurance Scheme (NEQAS) to ensure test consistency. Human resource development and laboratory-based research are also encouraged. The policy outlines a multitiered network for efficient service delivery (Ministry of Health, 2006).

#### **Strengthening Primary Healthcare Laboratory Services**

To improve services at the grassroots level, guidelines have been developed for Primary Medical Care Units (PMCUs). These cover basic infrastructure, infection prevention, and internal quality assurance. They promote patient-centred diagnostics and align with the Asia Pacific Strategy's focus on tiered services (Ministry of Health, 2018).

#### **Digital Transformation**

Sri Lanka is prioritizing digital health. The National Digital Health Guidelines and Blueprint aim to digitize laboratory services. They support interoperability between lab systems and clinical platforms and integration with the National Electronic Health Record (EHR). Improved communication infrastructure supports real-time reporting and surveillance (Ministry of Health, 2020).

#### **Data-Driven Planning and Monitoring**

Laboratory data is central to planning. The Annual Health Bulletin captures lab distribution, capacity, and usage. It provides performance metrics and identifies service gaps. This supports evidence-based decisions and highlights the lab system's role in surveillance (Ministry of Health, 2024).

#### **Strategic and Sectoral Plans**

Several documents support lab strengthening. The Health Master Plan (2016–2025) addresses infrastructure, HR, and service delivery. The Hospital Management Manual provides operational guidance for lab quality and safety. Sectoral strat-

egies for AMR, dengue, and COVID-19 incorporate lab services into disease control plans.

#### Moving Forward: Key Priorities for Sri Lanka

Looking ahead, the planned National CDC of Sri Lanka can play a central role in coordinating lab services. Key actions include operationalising NEQAS and expanding EQA/proficiency testing. A national laboratory strategy aligned with disease surveillance priorities is essential. Referral systems and service standards must be strengthened across all levels.

Addressing workforce shortages through training and updated curricula is critical. Expanding digital Laboratory Information Management Systems (LIMS), especially in district hospitals, will support real-time data use. Biosafety and biosecurity need to be institutionalised at all lab levels. Regular simulation exercises and After-Action Reviews (AARs) can improve emergency readiness.

CDC Sri Lanka should promote innovation, mobile labs, genomic surveillance, and sustainable financing. These steps will strengthen laboratory capacity and resilience.

#### Conclusion

A strong laboratory system is foundational to public health. Sri Lanka is making significant progress by aligning national strategies with global and regional guidance. Sustained investment, collaboration, and innovation will be crucial to building a resilient, efficient, and high-quality laboratory system.

Compiled by: Dr A W P Indumini Senior Registrar Epidemiology Unit Ministry of Health

#### **References:**

- 1. Ministry of Health, Sri Lanka. *Annual Health Bulletin* 2023. Colombo: Medical Statistics Unit; 2024.
- 2. Ministry of Health, Sri Lanka. *Health Master Plan 2016–2025 and Hospital Management Manuals*. Available at: www.health.gov.lk
- 3. Ministry of Health, Sri Lanka. *National Digital Health Guidelines*. Colombo: Health Information Unit; 2020
- 4. Ministry of Health, Sri Lanka. *National Health Laborato*ry *Policy*. Colombo: Ministry of Health; 2006
- Ministry of Health, Sri Lanka. Strengthening Laboratory Services in Primary Healthcare Institutions: Concept Note and Guidelines. Colombo, 2018
- 6. WHO. International Health Regulations (2005), Third Edition. Geneva: WHO Press; 2016
- WHO. Laboratory biosafety manual, 4th edition. Geneva: WHO Press: 2020
- 8. WHO. Laboratory Quality Management System Handbook. Geneva: WHO Press; 2011
- 9. WHO. *Strengthening public health laboratory services*. Available at: <a href="https://www.who.int">https://www.who.int</a>
- 10. WHO Regional Office for the Western Pacific. Asia Pacific Strategy for Strengthening Health Laboratory Services 2010–2015. Manila: WHO WPRO; 2010

Table 1: Selected notifiable diseases reported by Medical Officers of Health 03<sup>rd</sup>-09<sup>th</sup> May 2025 (19<sup>th</sup> Week)

Tak	ole 1	: S	elec	ted	not	ifiab	le c	lisea	ases	s re <sub>l</sub>	oort	ed k	y N	ledi	cal	Offic	cers	of	Hea	lth	03 <sup>rd</sup>	-09	th M	ay 2	2025	(19	9 <sup>th</sup> \	Nee	k)
	*.	100	100	100	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	91%	100	100	100	100	100	66	
WRCD	<u>*</u>	100	87	89	100	100	82	65	100	82	93	100	100	75	83	93	7	100	30	92	9	100	88	78	90	73	92	82	
	ľ	771	426	215	294	09	112	195	28	89	62	19	22	21	15	26	22	36	136	80	107	33	105	44	164	113	23	3304	
Tuberculosis	В																												
Tuber	<	33	35	16	16	7	6	22	0	_	4	0	က	က	4	7	_	0	13	0	∞	_	80	9	6	0	2	207	
-ia-		~	19	~	31	86	0	~	123	49	0	~	0	0	<b>←</b>	~	=	က	208	13	287	165	17	79	75	15	0	1208	
Leishmania-	B	0	<del>-</del>	0	က	9	0	0	4	7	0	0	0	~	0	0	<b>←</b>	0	2	0	7	œ	က	0	9	~	0	62	
	<	26	28	23	12	7	10	72	6	20	4	0	12	13	4	19	17	<b>о</b>	61	37	40	œ	33	23	22	47	17	643	
Meningitis	В	8	4	0	0	0	_	<u></u>	0	0	<del>-</del>	0	_	0	0	0	_	0	4	0	<del>-</del>	_	0	<u></u>	0	2	9		
Mer	⋖					53 (						7	. 41	20 (	17 (	06	. 22	29 (		) 92				. 22			) 82	9 27	
xodue	В	216	365	347	186	22	100	319	176	179	190		_	7	_	0	7	2	328	7	147	8	184	7	204	344	7	3919	
Chickenpox	<	~	21	23	14	4	_	13	4	13	10	~	0	~	0	2	3	2	13	က	က	5	6	5	6	<del></del>	9	177	
H. Rabiies	В	0	0	0	0	0	0	~	0	0	~	0	0	0	0	0	0	0	<b>←</b>	0	0	0	0	0	<del>-</del>	0	0	4	
H. Ra	⋖	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Viral Hep.	В	00	2	4	5	5	0	9	က	2	2	_	0	0	0	13	3	4	2	_	7	13	20	ω	4	7	~	124	
Viral	⋖	0	0 ,	0	0 ,	0	0 +	0	0 1	0	0 9	0	0 (	0	0	2	~	0	0	0	0 -	0	-	-	-	0	0	9	
R.	В	5	7	_	27	က	24	35	14	10	315	<del>-</del>	10	7	9	_	2	00	19	26	14	_	15	22	16	7	~	607	
Typhus F.	<	0	0	0	~	0	0	~	0	-	က	0	0	2	0	0	~	~	<b>←</b>	~	0	0	2	0	0	0	0	14	
siso.		187	296	286	120	97	52	333	195	208	115	53	18	20	46	46	92	8	367	155	230	118	150	311	269	289	21	4643	
Leptospirosis	B	0	12	7	2	တ	2	7	10	4	<del>-</del>	က	<del>-</del>	7	2	က	2	က	19	12	œ	8	4	တ	30	17	က	205	
	4	2	20	24	1	46	45	29	က	4	22	4	2	26	2	73	2	25	23	4	15	က	0	4	22	26	15	488 2	
F. Poisoning	В	0	4		_	က	_	0	0	_	_	0	0	0	0	က	0	0	0	0	0	0	0	0	0	_	က		
F. P.	⋖	4	1	5 11	4	0	,	0	0	, ,		4	0	-	1	0	0	0	1	0	3 (	-	3 (	0	3 (	ა ი	0	5 29	
En. Fever	В	0	. 0	0	0	0	0	0	0	0	0 10	0	0	0		0	0	0	0	0	0	0	0	0	0	2	0	2 55	
	⋖	8	22 (	9	2	_	4	о С	4	2	2	0	0	0	0	10	)	2	11	_	9	8	9	9	5	ω	2		
Encephalitis	В																											113	
Ence	4	0	2	0	0	0	0 0	0	0	0	0 6	8	4 0	0	0 +	~	0 2	0	1	0	0	0	0	0	0	3	10	ω	
ntery	В	15	22	23	31	12	30	21	1	7	39	ω	7	9	4	83	17	26	19	6	21	တ	16	0	71	37	15	565	
Dysentery	⋖	0	0	က	က	2	0	~	2	0	0	~	0	0	~	2	2	0	~	0	0	0	0	0	~	0	~	70	
ever		4691	2916	872	1209	631	86	762	358	674	592	52	94	37	32	1135	91	628	502	330	300	116	306	373	1849	550	219	19405	
Dengue Fever	8	310	194	63	27	23	7	32	16	17	<del>0</del>	~	<del>-</del>	0	<b>—</b>	29	4	22	30	12	<del>-</del>	10	7	10	242	43	13	125	
ے	<	(1)	-				/a		m									a)			ura	, a		_	. 4				
S		Colombo	Gampaha	Kalutara	φ	ale	Nuwara Eliya	ø.	Hambantota	373	Ja	Kilinochchi	nar	Vavuniya	Mullaitivu	Batticaloa	ara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	nlla	Monaragala	Ratnapura	alle	Kalmunai	SRILANKA	
RDHS		3	Gan	Kalı	Kandy	Matale	Nuw	Galle	Ham	Matara	Jaffna	Ϋ́	Mannar	Vavi	Mul	Batt	Ampara	Ę	Kur	Putt	Ann	Polc	Badulla	Mon	Ratr	Kegalle	Kalı	SR	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.lk). T=Timeliness refers to returns received on or before 09th May, 2025 Total number of reporting units 361 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

03<sup>rd</sup> - 09<sup>th</sup> May 2025 (19<sup>th</sup> Week)

Disease	No. o	f Case	s by F	Provinc	:e			Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date		
	W	С	S	N	Е	NW	NC	U	Sab	week in 2025	week in 2024	2025	2024	in 2025 & 2024
AFP*	00	01	01	00	00	0	01	00	00	03	00	26	31	-16.1%
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Mumps	00	01	01	01	03	01	01	00	00	08	08	89	110	-19.1 %
Measles	00	00	00	00	00	00	00	00	00	00	05	01	209	-97.6%
Rubella	00	00	00	00	00	00	00	00	00	00	01	01	02	-50%
CRS**	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %
Tetanus	00	00	00	00	00	00	00	00	00	00	00	02	02	0 %
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Japanese Encephalitis	00	00	00	00	00	00	00	00	00	00	00	04	01	300 %
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	12	06	100 %

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

### ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10